AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7198-7204

  Priolo, Carmen ^a   Pyne, Saumyadipta ^a,g,h   Rose, Joshua ^a   Regan, Erzsébet Ravasz ^b   Zadra, Giorgia ^a   Photopoulos, Cornelia ^a   Cacciatore, Stefano ^a   Schultz, Denise ^c   Scaglia, Natalia ^a,i   McDunn, Jonathan ^d   De Marzo, Angelo M ^c   Loda, Massimo ^a,e,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d METABOLON INC   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF HYDERABAD   (India)

^h PUBLIC HEALTH FOUNDATION OF INDIA   (India)

ⁱ INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE LA PLATA INIBIOLP   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; MYC PROTEIN; PROTEIN AKT1; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

AKT1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; GLEASON SCORE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF QUANTITATION; LIPID METABOLISM; MALE; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLIC FINGERPRINT; METABOLIC PARAMETERS; METABOLIC REGULATION; METABOLOMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, TRANSGENIC; NEOPLASM GRADING; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84918573255     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1490     Document Type: Article

References (20)

1. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta 2011;1807:1432-43.
2. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34.
3. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3.
4. Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol 2011;29:572-81.
5. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8.
6. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profi ling of human prostate cancer. Cancer Cell 2010;18:11-22.
7. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003;100: 7841-6.
8. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
9. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
10. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
11. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
12. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
13. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 2010;5:e9427.
14. Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, et al. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A 2007;104:17771-6.
15. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013;13:227-32.
16. Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010;1801:381-91.
17. Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC, Dittmer DP, et al. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci U S A 2012;109: 11818-23.
18. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
19. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, et al. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 2011;6:e17449.
20. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010;1:617-28.